Identifying predictors of antispasmodic use following robotic assisted simple prostatectomy

Area of Science:

• Urology
• Pharmacology

Background:

• Anticholinergic or ß-3 agonist use after robotic simple prostatectomy (RASP) is not well-documented.
• Understanding medication patterns and predictors is crucial for patient management.

Purpose of the Study:

• To determine the rates of antispasmodic medication use following RASP.
• To identify predictors associated with the need for these medications post-surgery.

Main Methods:

• Retrospective review of 255 RASP patients (2/2016-1/2020).
• Exclusion of patients without preoperative International Prostate Symptom Score (IPSS).
• Multivariable logistic regression analysis to identify factors associated with antispasmodic use.

Main Results:

• 8.6% of patients initiated antispasmodics post-RASP, with a median use duration of 6.5 months.
• Obstructive sleep apnea (OSA) was independently associated with increased antispasmodic use (OR 8.13).
• Continuous positive airway pressure (CPAP) treatment for OSA was not significantly associated with antispasmodic use.

Conclusions:

• Patients with OSA are significantly more likely to require antispasmodic medications after RASP.
• Tailored preoperative counseling for OSA patients may be beneficial.
• Further research into specific medication needs post-RASP is warranted.